| Name | Title | Contact Details |
|---|---|---|
Greg Rumple |
Chief Information Security Officer | Profile |
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.
Aurora Spine Corporation focuses on the development and distribution of spinal implant products for relieving back pain, and preserving spinal bone structure and anatomy in the United States. The company intends to provide interspinous process lumbar fusion devices for patients suffering from degenerative disc disease whose pain has not been eliminated by non-surgical treatment methods; polyether ether ketone interbody cages for use in spinal fusion procedures; and cervical and lumbar devices. It also plans to develop installation tools for surgeons. The company was incorporated in 2013 and is headquartered in Toronto, Canada.
Harbour Health Systems is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hyphen is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.